Nordic Life Science 1
Mads Krogsgaard Thomsen, CSO, Novo Nordisk BUSINE
S S D E A L Corvidia is a clinical stage company focused on the research and development of transformative therapies for cardio-renal diseases. CORVIDIA’S LEAD CANDIDATE, ziltivekimab, a fully human monoclonal antibody directed against Interleukin-6 (IL-6), is being developed to reduce the risk of major adverse cardiovascular events in chronic kidney disease (CKD) patients with atherosclerotic cardiovascular disease (ASCVD) and inflammation. Under the terms of the agreement, Novo Nordisk will acquire all outstanding shares of Corvidia for an upfront payment of 725 million US dollars in cash. Total payments to Corvidia Therapeutics shareholders could ultimately amount to 2.1 billion US dollars in cash upon the achievement of certain regulatory and sales milestones by Novo Nordisk. The acquisition of Corvidia Therapeutics and its lead candidate, ziltivekimab, is aligned with Novo Nordisk’s strategy to expand its presence across a range of cardiometabolic diseases that are closely linked to Novo Nordisk’s core business within diabetes and obesity. Ziltivekimab is being evaluated in a phase 2b dose-finding clinical trial in patients who have an increased risk of ASCVD with CKD and inflammation. PHOTO JANTZEN